"The reliance on Abiomed is being reduced as the company now has one additional, and potentially two additional, customers moving into volume production. "
If BOTH Nanodx & Nova BioMedical move into volume production over the remainder of the Sep 21 quarter and the Dec '21 quarter, we could feasibly be looking at Revenue for C2022 in excess of USD 20 million !!
QUESTION for HC Posters: At what stage does Sensera become a takeover target & at what price would TAKEOVER be successful.
In my opinion, once EITHER NanoDx or Nova BioMedical ramp up into volume production, the GAME is on. Any takeover would be unsuccessful at less than USD 100 million which equates to approx A$ 0.35 per share.
I think that if NanoDx get EUA before end of calendar year, my above estimate of Revenue for C2022 of USD 20 mill will be wildly under the mark. Look at the daily Covid figures around the world !!
At these levels Sensera is a NO BRAINER !
SE1 Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
